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Abstract
Background: In-silico virtual patients and trials offer significant advantages in cost,
time and safety for designing effective tight glycemic control (TGC) protocols.
However, no such method has fully validated the independence of virtual patients
(or resulting clinical trial predictions) from the data used to create them. This study
uses matched cohorts from a TGC clinical trial to validate virtual patients and in-silico
virtual trial models and methods.
Methods: Data from a 211 patient subset of the Glucontrol trial in Liege, Belgium.
Glucontrol-A (N = 142) targeted 4.4-6.1 mmol/L and Glucontrol-B (N = 69) targeted
7.8-10.0 mmol/L. Cohorts were matched by APACHE II score, initial BG, age, weight,
BMI and sex (p > 0.25). Virtual patients are created by fitting a clinically validated
model to clinical data, yielding time varying insulin sensitivity profiles (SI(t)) that
drives in-silico patients.
Model fit and intra-patient (forward) prediction errors are used to validate individual
in-silico virtual patients. Self-validation (tests A protocol on Group-A virtual patients;
and B protocol on B virtual patients) and cross-validation (tests A protocol on Group-
B virtual patients; and B protocol on A virtual patients) are used in comparison to
clinical data to assess ability to predict clinical trial results.
Results: Model fit errors were small (<0.25%) for all patients, indicating model fitness.
Median forward prediction errors were: 4.3, 2.8 and 3.5% for Group-A, Group-B and
Overall (A+B), indicating individual virtual patients were accurate representations of
real patients. SI and its variability were similar between cohorts indicating they were
metabolically similar.
Self and cross validation results were within 1-10% of the clinical data for both
Group-A and Group-B. Self-validation indicated clinically insignificant errors due to
model and/or clinical compliance. Cross-validation clearly showed that virtual
patients enabled by identified patient-specific SI(t) profiles can accurately predict the
performance of independent and different TGC protocols.
Conclusions: This study fully validates these virtual patients and in silico virtual trial
methods, and clearly shows they can accurately simulate, in advance, the clinical
results of a TGC protocol, enabling rapid in silico protocol design and optimization.
These outcomes provide the first rigorous validation of a virtual in-silico patient and
virtual trials methodology.
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Stress-induced hyperglycemia and high levels of insulin resistance are prevalent in cri-
tical care [1-4]. Increased counter-regulatory hormone secretion stimulates endogenous
glucose production and increases insulin resistance [3,4], elevating equilibrium glucose
levels and reducing the amount of glucose the body can utilize with a given amount of
insulin. Hyperglycemia worsens outcomes, increasing the risk of severe infection, myo-
cardial infarction, and critical illness polyneuropathy and multiple organ failure.
The occurrence of hyperglycemia, particularly severe hyperglycemia, is associated
with increased morbidity and mortality [2]. Glycemic variability and poor control are
independently associated with increased mortality [5-7]. Van den Berghe et al [8,9]
showed that tight glucose control (TGC) reduced intensive care unit (ICU) patient
mortality up to 45% using a target of 6.1 mmol/L. Other studies with similar or slightly
higher targets have successfully reduced mortality [10,11]. Hence, despite some diffi-
culty repeating these results [12], the data indicate that a control algorithm that safely
provides TGC to reduce hyperglycemia and glycemic variability can reduce mortality
and cost [13,14].
In this study, “virtual trials” are performed using a clinically validated model [15-17]
of the glucose-insulin system. Insulin sensitivity, SI, is used as the critical marker of a
patient’s metabolic state and is assumed independent of the insulin and nutrition
inputs. Virtual trials can be used to simulate a TGC protocol using a SI(t) profile iden-
tified hourly from clinical data and different insulin and nutrition inputs. Virtual trials
enable the rapid testing of new TGC intervention protocols, as well as analysis with
respect to glycemic control protocol performance, safety from hypoglycaemia, clinical
burden, and the ability to handle dynamic changes in patient metabolic state [15,18].
They are thus a means of safely optimising protocols prior to clinical implementation.
Virtual patient trials have been used in design of TGC protocols [16,19-21]. Others
have developed them for evaluating type 1 diabetes treatments [22,23] and in critical
care [24], but none have been specifically validated in comparison to clinical trial or
patient-specific outcomes. Specific to this study, the clinical results of SPRINT [11]
showed very close agreement to expected results from simulation [16,21]. However,
SPRINT was implemented in the Christchurch Hospital ICU, and all the clinical data,
models and virtual trial methods used to design it were from the same unit so it is not
an independent ICU in that sense.
Thus, the performance of virtual trials on separate matched cohorts has not yet been
evaluated. In addition, the assumption of the independence of a virtual patient’s insulin
sensitivity SI(t) profile from the insulin and nutrition inputs used to identify it from
clinical blood glucose (BG) data has never been validated. This study tests these
assumptions using clinically matched (virtual) cohorts based on clinical data from an
independent ICU, who were treated with two different glycemic control protocols in a
randomised trial. The independence of the ICU ensures a cohort who may be different
in treatment, insulin sensitivity or other factors [25] from patients in the Christchurch
ICU whose data underlie the development of the models and methods [16,19-21] vali-
dated in this study. Hence, there is no link between the patients used in this study and
the development of the models and methods being tested here. Hence, these clinically
matched cohorts allow this assumption of independence to be tested, as well as the
assessment of model errors in this virtual trial approach.
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Glucontrol Protocol and Patient Cohorts
The Glucontrol trial [26] randomised patients into two groups: Group A and Group B.
Group A received intensive insulin therapy and Group B received conventional insulin
therapy, with target ranges of 4.4-6.1 mmol/L and 7.8-10 mmol/L, respectively. Insulin
was administered as a continuous intravenous (IV) infusion. Hourly blood glucose
(BG) measurements were recorded when the glycemic level was not within the target
range. Otherwise, 2-hourly measurements were taken in the case of limited variation of
glycemia, defined as less than a 50% change from the previous glycaemia in 2-hour
range. Finally, 4-hourly measurements were taken when the glycemic level was less
than 50% of the highest glycemia of the four last hours. If other BG measurements
were taken, they were not recorded and did not result in changes to the insulin infu-
sion rate. The protocol specified insulin infusion rates are shown in Table 1 for the
intensive protocol used on Group A, and Table 2 for the conventional protocol used
on Group B. Nutritional input was left to local and/or clinician standards, and was not
explicitly considered in the Glucontrol TGC protocols.
In this study, data was used from 350 patients (175 in each arm) treated using the
Glucontrol protocol at CHU de Liege, Belgium, between March 2004 and April 2005.
Thus, the Glucontrol data used in this study is from only one centre out of the full
study [26]. The selection criteria for patients used in this analysis to generate virtual
patients with sufficient data density [15,16,27] are shown in Figure 1. Patients were
eliminated from the analysis if they received no insulin for their entire stay (per proto-
col), had less than 5 BG measurements or received little or no (recorded) carbohydrate
administration (in any form) for more than 48 hours of their stay.
Clinical details of the resulting cohorts are in Table 3 totalling 29,777 hours and
7,391 BG measurements. Patients in Group A were slightly older than Group B. How-
ever, there were no significant differences in sex, weight, BMI, severity of illness as
Table 1 Glucontrol Group A protocol (intensive). The starting insulin infusion rate is in
the top portion and the maintenance insulin infusion rates and increments are in the
bottom portion as labelled. All values converted to mmol/L from mg/dL in 27.
STARTING INSULIN INFUSION RATE SCALE
Glycemia Starting insulin infusion rate
<6.1 mmol/L On hold
6.1–7.8 mmol/L 1 U/h
7.8–10.0 mmol/L 2 U/h
>10.0 mmol/L 4 U/h
MAINTENANCE INFUSION RATE CHANGES
Glycemia Incremental insulin infusion rate
>16.7 mmol/L +3 U/h
10.0–16.7 mmol/L +2 U/h
7.8–10.0 mmol/L +1 U/h
6.1–7.8 mmol/L +0.5 U/h
4.4–6.1 mmol/L +0 U/h (target range)
2.2–4.4 mmol/L Stop insulin, Hourly measurement of glycemia until >80 mg/dl
<2.2 mmol/L Stop insulin, 10 gr glucose IVD, Call physician immediately, Hourly measurement of
glycemia until >80 mg/dl
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more carbohydrate, in alignment with its higher glycemic target.
Glucose-Insulin System Model
The analysis of patient-specific insulin sensitivity uses a glucose insulin system model
that has been clinically validated in several clinical TGC studies [17,19,28-30]:
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where: G(t) is total plasma glucose, I(t) is plasma insulin, and Q(t) is the effect of
previously infused insulin being utilized over time. EGPmax is the theoretical maximum
endogenous glucose production (EGP), which is suppressed with increasing glucose
concentrations. This suppression, independent of non-insulin mediated glucose uptake
by the central nervous system (CNS)i sc a p t u r e db yt h et e r mpG. In contrast, patient-
specific insulin mediated glucose removal is captured with insulin sensitivity, SI,w h i c h
is identified (hourly) from clinical data as a time-dependent variable that reflects evol-
ving patient condition [15,18,27,31]. Exogenous inputs are glucose appearance P(t)
from the carbohydrate content of nutrition infusions via a two compartment model
[19], and intravenous insulin administration uex(t). The remaining parameters are phy-
siologically defined population constants for transport rates (n, k), saturation para-
meters (aG, aI), endogenous insulin secretion (IB, kI)o rv o l u m e s( VG, VI)t h a th a v e
been validated over several studies.
Table 2 Glucontrol Group B protocol (conventional). (a) Starting insulin infusion rate. (b)
Maintenance insulin infusion rates and increments. All values converted to mmol/L from
mg/dL in 27
STARTING INSULIN INFUSION RATE SCALE
Glycemia Starting insulin infusion rate
<10.0 mmol/L On hold
10.0–13.9 mmol/L 1 U/h
13.9–16.7 mmol/L 2 U/h
>16.7 mmol/L 4 U/h
MAINTENANCE INFUSION RATE CHANGES
Glycemia Incremental insulin infusion rate
>16.7 mmol/L +3 U/h
13.9–16.7 mmol/L +2 U/h
10.0–13.9 mmol/L +1 U/h
7.8–10.0 mmol/L +0 U/h (target range)
4.4–7.8 mmol/L Decrease 50% rate insulin
2.2–4.4 mmol/L Stop insulin, Hourly measurement of glycemia until >80 mg/dl
<2.2 mmol/L Stop insulin, 10 gr glucose IVD, Call physician immediately, Hourly measurement of
glycemia until >80 mg/dl
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to insulin and nutrition inputs is insulin sensitivity, SI.I ti si d e n t i f i e db yf i t t i n gt h e
model to BG measurements, and insulin and carbohydrate administration inputs, from
retrospective clinical data for each protocol [27,32]. The resulting insulin sensitivity
profile, SI(t), identifies a unique value every hour and the resulting profile thus varies
Figure 1 Cohort selection for Glucontrol A (Intensive) and B (Conventional) insulin therapy groups,
resulting in 211 total Glucontrol patients being retained from the original 350. Note that each arm of
the trial (A and B) each had 175 patients, so that 33 were removed from Group A and 106 from Group B.
Table 3 Glucontrol Group A and B comparison. P-values are computed using chi-squared
and Mann-Whitney tests. values are median [IQR] as appropriate.
Cohort A B P value
Baseline Variables
Number patients 142 69
Male percent (%) 64.8 56.5 0.25
Age 71 [61 - 80] 69 [53 - 77] 0.035
Weight 72 [62 - 85] 75 [68 - 81] 0.38
BMI 25.4 [22.6 - 29.3] 26.0 [23.2 - 29.3] 0.46
APACHE II 17 [14 - 22] 17 [14 - 21] 0.76
Initial BG (mmol/L) 6.6 [5.6 - 8.6] 6.6 [5.7 - 9.4] 0.58
Glucose Control
Total hours 16, 831 12, 946
BG measurements 4, 571 2, 820
BG (mmol/L) 6.3 [5.3 - 7.6] 8.2 [6.9 - 9.4]
Insulin rate (U/h) 1.5 [0.5 - 3.0] 0.7 [0.0 - 1.7]
Carbohydrate admin (all sources) (mmol/min) 0.30 [0.00 - 0.90] 0.60 [0.10 - 1.00]
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been validated in TGC clinical trials in adults and neonates [17,19,28-30] and SI has
also shown good correlation to gold standard euglycemic clamp data [33,34].
Sensitivity analysis has shown this approach can capture the clinically observed
dynamics and variation. Median BG data fit and 1-2 hour forward prediction errors are
within 2-10% compared to measurement errors of 7-12%. Hence, this model and meth-
ods have been used to analyse, develop and/or implement new protocols
[16-18,21,25,28-30].
Insulin Sensitivity Dynamics
The dynamics of insulin sensitivity variability can be compared between cohorts. Ker-
nel density modeling provides a smooth, physiologically realistic description of the
hour-to-hour changes in insulin sensitivity, SI [15,18,35]. Confidence intervals for these
stochastic models of hourly variation can be visually compared to indicate whether
cohorts exhibit similar insulin sensitivity, and thus metabolic, variability [25], as a
further, clinically relevant and important comparator of TGC cohorts.
Virtual Trials
The “virtual trial” method is used to simulate a trial using patient specific data. The
insulin sensitivity profile SI(t) identified from clinical data captures a patient-specific
time varying glycemic response to the given insulin and nutrition inputs. This SI(t)
profile can then be used to simulate the blood glucose response to other combinations
of insulin and dextrose inputs specified by a modified TGC protocol to obtain new in
silico glycemic responses [16]. Hence, an expected blood glucose profile can be gener-
ated for each patient to simulate patient-specific glycemic responses to a specific pro-
tocol. Thus, virtual trials can be used to analyse, in silico, the effect of different TGC
protocols on patient-specific glycemic performance. Figure 2 shows this overall
process.
The critical assumption is that the identified SI(t) profiles are (largely) independent of
the clinical data used to derive them. In this analysis, 2 groups of virtual patients are
created from randomised clinical trial data. Groups A and B are defined by whether
they were clinically treated with either the Glucontrol A (intensive) or Glucontrol B
(conventional) TGC protocols. Using matched cohorts treated differently allows this
assumption to be tested. The hypothesis is thus defined: if SI(t) is independent, similar
control results would be achieved in the cross-validation.
Validation Analysis
This study performs three major forms of validation using virtual trials. These three
tests provide both per-patient and cohort-wide validation of this in silico approach.
1) Model Fit and Prediction Error
Model fit and prediction errors are used to show the ability of the model to fit the data
and predict the expected patient state. Using the identified SI profiles, the simulated
BG measurements were compared to clinical BG data. This fit error quantifies the abil-
ity of the model to capture the observed dynamics.
Prediction results are generated by holding insulin sensitivity, SI constant for an
upcoming hour, and simulating the BG one hour into the future using the recorded
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recorded BG or a linear estimate between 2-hourly measurements. Prediction errors
assess the ability of the model and identified parameters to predict intervention out-
comes and is highly relevant for validating models used in model-based TGC [16,36].
Prediction errors are thus an assessment of the model’s ability to make accurate
patient-specific prediction. Given low fit errors it thus also assesses whether the identi-
fied and given model parameters are accurate. In this study, prediction error serves to
validate the model identification method [27] and approach [16,21] used to create vir-
tual patients and virtual trials.
2) Self-Validation
Self validation tests the ability of the in silico virtual patient modelling method to
reproduce the clinical data from which a virtual cohort was derived. For the self valida-
tion on Glucontrol A, the Glucontrol A protocol defined in Table 1 is simulated on
Group A virtual patients, and these virtual trial results are compared to the clinical
data from Group A. This step was repeated for self validation on Glucontrol B.
Differences between clinical and virtual trial results can be ascribed to model errors,
and/or lack of perfect compliance in the clinical study versus the perfect compliance
and timing in silico. Hence, two self-validation virtual trials were simulated on each
group considering: a) the actual measurement timing used in the clinical trials (actual
measurement) and b) measurement timing from the protocol (per protocol). Compar-
ing actual and per-protocol measurement timing allows one to assess one aspect of
compliance error.
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Figure 2 Virtual patient development and in silico simulation method. (I) Clinical data are used for
fitting insulin sensitivity profiles to create ‘virtual patients’. (II) These virtual patients can be used for
simulating different protocols.
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follows the measurement timing in the clinical trials where the controller selects the
proper intervention in response to the BG va l u e sa tt h ee x a c tt i m ec o r r e s p o n dt oi t s
clinical time. In contrast, per protocol self validation follows exactly the Glucontrol A
and B protocols defined in Tables 1 and 2 regardless of the measurement timing they
had clinically. The controller will still select the intervention according to the current
BG values. However, because the Glucontrol protocols modify insulin by increments to
a prior infusion rate in Tables 1 and 2, different measurement timing could signifi-
cantly change dosing, which would thus indicate the impact of compliance to measure-
ment timing.
3) Cross-Validation
Cross validation uses the matched A and B cohorts to determine the ability of the
modelling method to reproduce the clinical data on a matched, but independent,
cohort. Thus, Protocol A is simulated on virtual patients derived from Group B clinical
data, with results compared to clinical data from Glucontrol Group A. Similarly, Proto-
col B is tested on virtual patients from Group A and the results are compared to
Group B clinical data.
In theory, if patients were perfectly matched in all ways, the in silico and clinical data
would also match if the in silico virtual trials method were exact. Differences using
large matched cohorts can thus be largely ascribed to how well the assumption holds
that these virtual patient SI(t) profiles are independent of the clinical insulin and nutri-
tion inputs used to derive them. If cross validation results match the clinical results
well, for clinically matched cohorts, then this assumption can be considered valid.
Hence, this validation tests the underlying assumption of this virtual trial method.
Figure 3 shows the self-validation and cross-validation processes schematically.
Results
Metabolic Variability
Figure 4 shows the 5
th -9 5
th percentile range, IQR and median probability bounds for
stochastic models for Group A and Group B. The distributions indicate the hour to hour
intra-patient metabolic variability in SI is very similar across the majority of the SI range,
particularly for the middle 50% (IQR). In particular, 89%-93% of the data for both groups
was in the range 0.01 × 10
-3 ≤ SI ≤ 0.8 × 10
-3, which is where there was greatest agreement
between the groups. Above this range sparse data had an effect, particularly on the 5% and
95% bounds. Hence, the clinically matched cohorts of Table 3 are also similar in metabolic
variability, which is significant evidence of similar metabolic response and variability in
response to insulin across patients and cohorts that is important in this analysis.
Fit, Prediction Validation
Figure 5 shows the model fit and prediction errors for the entire Glucontrol cohort
(A + B), and separated into Group A and Group B. Results are shown on a cohort and
a per-patient basis. Model fit error was consistent across all three groups analysed,
with median fit error <0.25% in all cases. Group B has the lowest prediction error
among these three distributions. The Glucontrol (A + B) cohort prediction error med-
ian value was 3.5%, whereas Group A and Group B were 4.3% and 2.8%, respectively.
All these median errors are below typical sensor errors of 7-12%.
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model to accurately capture insulin and glucose dynamics. Figure 4 indicates variability
in insulin sensitivity is similar (within 2% for all ΔSI) for the cohorts. Thus, the model
prediction errors for Group A and B have 80% or more of their results ≤10% measure-
ment error, despite significant differences in clinical insulin usage in Table 3. This per-
formance across different cohorts is similar in a clinical sense where relatively smaller
errors of 10-12%, or differences in error of 2-5% are not clinically significant in out-
come. However, it should be noted that they are not statistically the same. Similar
results are seen for the median patient fit and prediction errors in the lower panel of
Figure 5.
Self & Cross Validation
Figure 6 shows the CDF of measured blood glucose on a cohort basis, comparing clini-
cal data from Glucontrol A and B to:
1. Self validation: Per protocol and actual measurement virtual trial results for Glu-
control A and B on the Group A and Group B virtual patients.
Group A 
Virtual patients 
Glucontrol A 
Control Protocol 
Simulation Code 
Group B 
Virtual patients 
Glucontrol B 
Control Protocol 
Simulation Code 
Self Validation: expect to generate original clinical data with 
differences being due to compliance or model errors 
 
Cross Validation: expect to generate clinical data of one 
group using virtual patients from another (matched) group with 
errors due to the validity of assuming independence of the 
virtual patients (SI(t)) from the clinical inputs used to identify it. 
Group A  
Clinical Data 
Self Validation 
Cross 
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Cross 
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Clinical Data 
Group B  
Clinical Data 
Group B  
Clinical Data 
Figure 3 Virtual trial validation method. These profiles are then used to re-simulate the Glucontrol A
and Glucontrol B protocols for comparison to the appropriate clinical results.
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Page 9 of 182. Cross validation: Virtual trial results for the Glucontrol A protocol on Glucon-
trol B virtual patients, and the Glucontrol B protocol on virtual Group A patients.
The breakdown of distributions shows a clear separation between the Glucontrol A
and Glucontrol B protocols, as expected from the clinical results, and equally for all
combinations of simulations.
The four distributions for the Glucontrol A protocol show particularly close agree-
ment. The Glucontrol A clinical median cohort BG value of 6.2 mmol/L agrees well
with the 6.0 mmol/L and 6.2 mmol/L medians for the self validation trials using actual
and per-protocol BG measurement timing respectively. The cross-validation median
BG of 6.5 mmol/L is also in close agreement with the clinical result.
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Stochastic models are generated for data where the BG measurement interval was 1-2 hourly [22].
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spread in results, particularly below the Group B target of 8 mmol/L. However, the
median cohort clinical BG value of 8.1 still agrees well with the medians of 8.5 and 8.7
mmol/L for Glucontrol B self validation with actual and per-protocol measurement fre-
quency, respectively. It also agrees well with the cross-validation median result of 8.5
mmol/L. The cross validation result lies between the clinical data and self validation
result indicating it is within the model and/or compliance error compared to the clini-
cal data.
Finally, the wider error in the Glucontrol B protocol results may be due to the rela-
tively low median insulin doses of <1 U/hr (Table 3). Hence, model error grows due to
the fixed endogenous insulin rate assumed for IB in this situation and similarly fixed
value assumed for EGPmax. Finally, as with the Group A results, the self and cross vali-
dation agreement is within measurement error and clinically insignificant over the
CDF.
Figure 7 shows the same results for the CDF of the median patient blood glucose
levels across all patients in each group. This “per-patient” comparison has the same
whole-cohort trend in Figure 6. Interestingly, and as with the cohort results, the largest
gap is between self validation and clinical data for Glucontrol B.
Overall, the gap between the self validation using actual measurement timing and
clinical data indicates the possibility of compliance error. In contrast, the difference
between self validation simulations using exact protocol-specified timing and the clini-
cal data shows one possible indication of model error. However, it may also suggest
that the conventional, lower intensity Group B protocol may not have been followed as
strictly with respect to dosing.
Table 4 shows the comparison of clinical trials to the self validation and cross valida-
tion on Glucontrol A. Per patient results show a reasonably close agreement between
self validation per protocol to the clinical data but the insulin rates are higher given
the almost 2× higher measurement rate when using the protocol-specified rules. Using
the actual measurement rate, the insulin rates are closer.
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Figure 6 CDF of blood glucose levels of clinical Glucontrol data versus virtual trials on a cohort
basis. The A and B cohort sets of (3) curves are labeled.
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Page 11 of 18Differences in measurement rate and insulin dose can be ascribed to non-compliance
and due to the design of Glucontrol, where the rate of change of insulin dose is tied to
BG measurement frequency. In particular, the clinical and actual measurements were
taken 52.0% of the potential per-protocol specified times based on in silico glycemic
results for Glucontrol A and 63.5% for Glucontrol B in Table 5. Note that Glucontrol
B had a higher compliance rate (% of per-protocol measurements) likely due to its
higher glycemic target, which allowed 4 hour measurements to start sooner than for
Glucontrol A. Thus, it could be construed that Glucontrol A clinical staff were less
compliant to a potentially more burdensome protocol in this regard.
For the cross validation, the Glucontrol A protocol required almost 3× higher rates
of insulin for Group B, compared to the clinical data. However, this may be a function
of the interaction of protocol and measurement frequency where there was a 1.4× dif-
ference that results from per protocol versus actual measurement self-validation. That
said, the Glucontrol B patients received 2.6× greater carbohydrate input to offset much
of this difference in insulin administration. Specifically, the cross validation in Table 4
required 3.2× more insulin to offset 2.6× more carbohydrate administration. Adjusting
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Figure 7 CDF of median blood glucose measured of Glucontrol clinical data versus virtual trial on a
per patient basis. The A and B cohort sets of (3) curves are labeled.
Table 4 Comparison of per-patient clinical results and virtual trial simulations (self-
validation and cross validation) on Glucontrol A. Clinical and actual measurements were
taken 52.0% of the potential per-protocol specified times based on in silico glycemic
results. Median [IQR] is used where appropriate
Self validation Cross validation
Clinical Actual Measurement Per-Protocol Per-Protocol
No. of patients 142 142 142 69
Per Patient Results
Insulin rate (U/h) 1.4 [0.9 - 2.1] 1.8 [1.1 - 2.9] 2.5 [1.5 - 4.1] 4.5 [2.3 - 6.5]
Glucose rate (g/h) 1.1 [0.5 - 7.6] 1.1 [0.5 - 7.6] 1.1 [0.5 - 7.6] 2.9 [0.7 - 7.4]
BG (mmol/L) 6.4 [5.9 - 6.9] 6.2 [5.7 - 6.8] 6.2 [5.7 - 6.8] 6.5 [6.0 - 6.9]
BG measures 4564 4564 9467 7259
Measurement frequency
(measurement/patient/day)
6.52 6.52 13.54 13.48
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Page 12 of 18by 2.5/1.8 the per-protocol versus actual measurement increase in insulin administered
yields an estimated 2.4× increase in insulin use to offset this increased carbohydrate
administration. Hence, the increased insulin in cross validation in Table 4 is primarily
due to the increased carbohydrate administered to Group B.
Comparison of clinical trials with self validation and cross validation on Glucontrol B
is summarized in Table 5. Self validation results show close agreement to the clinical
result and for cross validation lower Group A insulin requirements are reflected by the
lower nutrition given that group and the higher target BG target under the Glucontrol
B protocol, which is similar to the difference in insulin in the cross validation in Table
4 but in the reverse direction. Similarly, virtual trials of Glucontrol B per protocol have
higher measurement frequency compared to the actual measurement indicating signifi-
cant non-compliance. Thus, the actual measurement case indicates closer agreement
with the insulin given and glycemic outcomes, as with the Glucontrol A results.
Discussion
This paper focuses on the Glucontrol protocol from one centre (Liege, Belgium; pilot
centre). Glucontrol was a multi-centre study stopped early due to a high rate of unin-
tended protocol violations [26]. Hence, some self-validation errors may be the result of
poor compliance, as seen in the results of Tables 4 and 5, and thus the different virtual
trials can capture that reality. Patient-specific compliance levels ranged from 100%
compliance to 20%. However, these values are skewed by length of stay and initial gly-
cemic levels among other possible factors, and thus per-patient statistics are only
broadly meaningful.
The clinical data was independent from the Christchurch Hospital ICU data used in
prior development and clinical validation of the model employed here. More impor-
tantly, there are 2 cohorts matched by severity of illness, weight and sex, which had
significantly different glycemic targets and glycemic control therapies. In addition, Fig-
ure 4 shows that cohorts appear well matched in their metabolic dynamics and varia-
bility which is the critical aspect for this study as it determines the outcome glycemia
and variability for a set of given interventions.
One possible limitation is that unequal numbers of virtual patients are created from
each cohort (A = 142 of 175 are used; B = 69 of 175), as seen in Figure 1. The reason
is that the higher glycemic target of Glucontrol B, and lower compliance, meant that
Table 5 Comparison of per-patient clinical results and virtual trial simulations (self-
validation and cross validation) on Glucontrol B. Clinical and actual measurements were
taken 63.5% of the potential per-protocol specified times based on glycemic results.
Median [IQR] is used where appropriate
Self validation Cross validation
Clinical Actual measurement Per protocol Per protocol
No. of patients 69 69 69 142
Per Patient Results
Insulin rate (U/h) 0.6 [0.3 - 1.2] 0.5 [0.2 - 1.0] 0.6 [0.2 - 1.4] 0.2 [0.0 - 0.8]
Glucose rate (g/h) 2.9 [0.7 - 7.4] 2.9 [0.7 - 7.4] 2.9 [0.7 - 7.4] 1.1 [0.5 - 7.5]
BG (mmol/L) 8.3 [7.6 - 8.8] 8.4 [7.8 - 9.1] 8.7 [8.1 - 9.5] 8.3 [7.4 - 9.1]
BG measures 2820 2820 4448 5772
Measurement frequency
(measurement/patient/day)
5.23 5.23 8.23 8.23
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Page 13 of 18far more patients did not meet the criteria in Figure 1 required to create valid virtual
patients due to low data density. However, Table 3 shows that these patients are still
matched clinically in the most relevant clinical parameters for survival (APACHE II
and initial BG). Additionally, as noted in the results and shown in Figure 4 insulin sen-
sitivity and its variation are similar. As a result, the virtual patients are also equivalent
in underlying data quality and clinically important metrics. However, a larger cohort
would allow more detailed cross validation on sub-cohorts. Hence, this potential lim-
itation does not appear to skew the results presented or their validity.
Further, despite significant differences between the two protocols, the hour-to-hour
intra-patient variation between cohorts is very similar, indicating hour-to-hour changes
in insulin sensitivity are patient-specific and protocol-independent. The cohorts can
thus be considered interchangeable for the purpose of the cross validation presented.
This result also helps independently validate the assumption that this model-based
insulin sensitivity is independent of the clinical inputs used to identify it, which is
important as this assumption is the basis of these virtual trials.
The model fit errors in Figure 5 are relatively very small and almost overlaid for
Group A, B and the entire Glucontrol cohort. The model prediction validation results
in Figure 5 can be seen as an estimate of the variability of insulin sensitivity in this
cohort, as well as a sign of model fitness. Low 1-hour prediction errors compared to
sensor error of 7-12% were found for both groups. For context, this result also suggests
the use of model-based targeted BG control will be effective for these cohorts of criti-
cally ill patients, as demonstrated previously for Christchurch ICU cohorts upon whom
this model was derived and used [16,19,36]. Thus, they also serve as an independent
validation of this model using different ICUc o h o r t s .N o t et h a ts i m i l a r ,b u tl a r g e r ,
errors for 2-4 hour predictions have been found for this model [27]. The growth of
such error is largely due to the greater chance of significant variation in SI over longer
time periods as the hourly variations in Figure 4 compound. However, it should be
noted that in this scenario, 1-hour and 2-hour predictions are clinically relevant.
The distribution of clinically measured BG values shows a very clear difference
between Glucontrol protocol A and B, as expected. The virtual trials results are within
5% (median) of the clinical results for both the self validation and cross validations
(Figures 6 and 7). Referring to the same figures, the obvious separation between two
protocols indicates the inter-protocol differences are, as expected, much larger than
any inter-group differences thus supporting the fundamental assumptions behind this
virtual trials approach. More importantly, the close correlation of self and cross valida-
tion results to clinical data validates the idea that these in silico virtual trial simulations
can accurately predict the expected clinical results of a TGC protocol prior to clinical
implementation.
The results in Figures 6 and 7 illustrate some variation between clinical data and vir-
tual trials. In particular, Glucontrol A results are closer to the clinical data compared
to Glucontrol B. The major difference is that Protocol B uses much less insulin given
its higher glycemic target. Therefore, the impact of intrinsic and potentially variable
patient-specific dynamics, such as endogenous insulin production (IB and kI) and endo-
genous glucose production (EGPmax), are more pronounced with respect to the far les-
ser exogenous insulin given to Group B, especially at blood glucose levels below 8.0
mmol/L. As these metrics are unidentifiable and thus, by necessity, assumed
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Page 14 of 18population constants, some of the Group B simulation errors may reflect errors in
these population values. In particular, IB can have a very wide range of patient-specific
values, and may also vary over time and patient condition [37]. However, if this differ-
ence from the assumed value was significant, the variability in Figure 4 would have
been potentially greater than observed. Similarly, the value of kI (endogenous insulin
suppression by exogenous administration) can also vary by time and condition [37], as
well as across cohorts administering different levels of insulin (Tables 4 and 5). How-
ever, while this may be one possible cause of the slight shift seen in Figure 6 for the
Glucontrol B results, significant differences between model and clinical behaviour
would have been evident in Figure 4 and in the prediction errors and glycaemic out-
comes of Figures 5, 6 and 7.
A further and potentially more likely cause is evident in Figure 6 where the most mis-
matched line of the three results is for the clinical results for Glucontrol B, where the
simulation results are more similar. The fact that the clinical data are lower than the
simulations in this region could indicate non-compliance in timing or dosing of insulin,
or simple overriding of the protocol recommendations by clinical staff. Computer simu-
lations will always follow protocols exactly as instructed. Hence, the self validation error
captures both model and compliance errors, which are clearly evident in Table 5 where
insulin doses and protocol-specified measurement frequency are very different from the
actual measurement case. This last point is critical because reduced measurements in
the B protocol would not reduce insulin as fast as the per protocol case, resulting in
lower clinical BG levels. The actual measurement self-validation simulation for Glucon-
trol B is much closer to the clinical data, having accounted for this effect.
For the cross validation, Protocol A on Group B is a very good match with errors
similar to the self validation results for Group A. In addition, Protocol B on Group A
virtual patients is within a similar range as the Group B self validation and close to the
slope and trends of the clinical data. Thus, the insulin sensitivity independence
assumption behind this virtual trials approach holds, independently validating this con-
cept and the virtual trial method based on this model.
Differences between self and cross validation results are ascribed here to remaining
differences between patient groups, despite clinical matching. The main notable differ-
ence pointed out in the results and Tables 4 and 5 is the difference in nutrition given
each cohort. The virtual trials approach here treats each group as being treated differ-
ently, including the carbohydrate and glucose infusions administered. These infusions
were patient-specific and specified based on local and individual clinician standards,
rather than per a protocol of any type. Thus, they were kept for each patient. As a
result, Glucontrol B patients with the higher target had 2.6× higher glucose administra-
tion, which in cross validation was offset by 3.2× more insulin in the virtual trials. Dif-
ferences in insulin rates between per protocol (as the cross validation was done) and
per actual measurement rates makes these differences almost equal at 2.6× higher glu-
cose administration and 2.4× greater insulin required to achieve the almost identical
glycemic outcomes. Hence, the patients display similar overall insulin sensitivity, and
the virtual trials took independently treated, matched patients and achieved the same
outcome despite different initial treatments in the clinical data used to create the vir-
tual patient. More specifically, nutritional treatment differences, within reason, did not
affect or influence the results outside of expectations.
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insulin sensitivity as a description of patient metabolic state, rather than as a therapy-
specific parameter value. Other causes for remaining differences may also be a function
of remaining model approximations or errors. As noted, inter-patient variability in
some fixed model parameters is at least one cause of model limitations and errors.
However, the limited glucose data with no added or real time insulin data limits the
ability to uniquely identify these parameters [27,32].
Finally, this paper shows the potential for TGC protocols to be readily optimised and
implemented using model based TGC. The low prediction errors indicate an ability to
minimize the risk of hypoglycaemia as well as provide tight control. Even though some
TGC clinical trials have not achieved any benefit from TGC [12,38], only 2 protocols
have been first optimized with virtual trials [11,17,21]. Both delivered safe, effective
TGC with reduced or zero hypoglycaemia.
Conclusions
This paper presented the analysis and validation of an in silico virtual patient and
model-based virtual trials methodology. The validation approach, as presented, is read-
ily generalized. It takes advantage of a set of independent clinical data comprised of
two clinically matched cohorts treated with two different TGC protocols with two dif-
ferent glycemic targets. Three main conclusions can be drawn:
￿ Self validation indicated a clinically insignificant error in these virtual patient
methods due to model and/or clinical compliance. They also showed the impact of
some non-compliance independent of model error.
￿ Cross validation clearly showed that the virtual patient methods and models
enabled by patient-specific SI(t) profiles are effective and the assumption that the SI
(t) profiles are independent of the clinical inputs used to generate them holds.
￿ Thus, the virtual patients and in silico virtual trial methods presented are vali-
dated in their ability to accurately simulate, in advance, the clinical results of an
independent TGC protocol, directly enabling rapid design and optimisation of safe
and effective TGC protocols with high confidence of clinical success.
Overall, this study further shows the potential and capability of model-based, data
driven in silico methods to aid protocol design, as well as the potential for models to
provide accurate, safe and effective real-time TGC.
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